Clinical Points
===============

1.  ■ Virtually all respondents who recommend the use of bright light therapy recommend its use in seasonal depression, whereas only half of those who recommend bright light therapy do so for nonseasonal depression.

2.  ■ Cost was identified as the leading barrier to recommending the use of bright light therapy---a factor that was cited by over half of the respondents.

3.  ■ The leading modifiable barrier to recommending bright light therapy use is lack of knowledge regarding this treatment modality.

Bright light therapy is among the first-line interventions for seasonal affective disorder (SAD), a practice buttressed by over 70 clinical trials.[@bib1] Bright light therapy is also efficacious for nonseasonal major depression[@bib2],[@bib3] and various sleep disorders, particularly those with circadian rhythm disturbances.[@bib4] Since the American Psychiatric Association--sponsored publication in 2005 by Golden and colleagues,[@bib2] data continue to expand on the efficacy of bright light therapy in nonseasonal depression among the chronically depressed,[@bib5] elderly,[@bib6] pregnant,[@bib7] and nonperimenopausal women.[@bib8] Studies investigating bright light therapy as an adjunct to serotonergic antidepressants have also revealed that the treatment hastens antidepressant response and remission when administered as a solo adjunct[@bib9],[@bib10] or in conjunction with other chronotherapeutic interventions including wake therapy.[@bib11]

Beyond its efficacy for select psychiatric illness, bright light therapy is eminently safe and more rapidly efficacious than medications or psychotherapy for seasonal and nonseasonal depression.[@bib2],[@bib12] Furthermore, bright light therapy is one of a small handful of treatments---including intravenous ketamine, electroconvulsive therapy, and other chronotherapies---that treats depression in days.[@bib13] Despite the myriad potential benefits for incorporating bright light therapy in the management of several psychiatric and circadian rhythm disorders, data remain limited as to its use, particularly in the United States. We conducted an e-mail survey of members of the Massachusetts Psychiatric Society regarding attitudes on the use of bright light therapy among psychiatrists, with an emphasis on its use in seasonal and nonseasonal depression.

A recent survey of psychiatrists in German-speaking countries revealed that bright light therapy is widely used in parts of Europe[@bib14]; however, to our knowledge, no comparable study has been conducted in the United States. Personal experience, correspondence with peers, and other anecdotal data suggest that bright light therapy is significantly less utilized in the United States than in Europe, as was found in a previous survey.[@bib14] Our current survey investigated attitudes on bright light therapy among practicing psychiatrists in the United States.

Quantitative data on the use of bright light therapy are complicated by regulatory, logistical, proprietary, and financial factors. First, light-delivery devices do not qualify as durable medical equipment by US regulatory agencies (42 US Code § 1395x, subsection n), and they are not approved by the US Food and Drug Administration (FDA) for any medical conditions, including mood or circadian rhythm disorders. As a result, a very limited number of insurance companies reimburse patients for the cost of these devices. Logistically, although physicians may recommend or be said to "use" bright light therapy, they do not prescribe it in a strict sense. Accurate prescribing patterns of physicians may be obtained in several ways (eg, European countries with population-wide registries or among subsets of the US population such as the Veterans Administration or Medicare); however, the same cannot be achieved in relation to light-delivery devices. This lack of prescribing patterns prevents population or nationwide surveys of bright light therapy use parallel to the methodologies implemented for medication prescriptions.

Next, proprietary light-delivery devices are produced by private companies, and their manufacture is not overseen federally. Patients may also purchase light-delivery devices either directly from manufacturers or through secondary online or brick-and-mortar vendors, further confounding accurate assessments of prevalent use. On a practical and more fundamental level, one cannot patent light, which doubtless hinders industry-sponsored research in this arena. Manufacturers continue to evaluate novel light-delivery devices such as light visors, light books, or other hand-held devices resembling e-readers or light-diffusing devices that emit biologically informed light spectra. It remains conceivable that a company may yet obtain patent protection for such a light-delivery device.

We expected that a lower proportion of psychiatrists in Massachusetts would recommend the use of bright light therapy compared to those reported in Europe. Secondary analyses compared the proportion of respondents who consider bright light therapy efficacious either as monotherapy or as adjunctive therapy for the conditions defined by Fischer and colleagues.[@bib14]

METHOD
======

The Massachusetts Psychiatric Society provided a list of member e-mails for this research project, and we employed an English version of a previous survey used by Fischer and colleagues (Appendix 1).[@bib14]

The majority of the original questionnaire was kept intact in order to allow for direct comparisons between the data reported previously and current findings. Demographic information including level of training, practice type and setting, duration of medical practice, and gender were also requested on a voluntary basis. A Web domain ([http://www.bmcchronotherapeutics.com](http://www.bmcchronotherapeutics.com/)) was created to host this survey, and the questionnaire was managed via a secure account through Adobe FormsCentral (<https://new.acrobat.com/en_us/products/formscentral.html?s_tnt=66820:1:0>). A request to complete the survey was sent out via the primary author's personal institutional e-mail account to limit the chances that the e-mail would be filtered out by recipients' accounts. Two follow-up e-mails were sent at roughly 1-week intervals to solicit additional respondents---one by the primary author and another by the executive director of the Massachusetts Psychiatric Society. Responses were obtained from March 2--24, 2013.

To incentivize completion, we indicated that a 32 GB iPad would be raffled off to a respondent at the conclusion of the online survey, and this information was also included in the title of the third e-mail invitation. The survey allowed respondents to indicate an e-mail address and name to be entered for the iPad raffle. It was explained that all response information would be anonymized, and names and e-mail addresses would be destroyed following identification of an iPad recipient. We anticipated a response rate greater than 30%. All data were analyzed using R, a free software environment for statistical computing ([www.r-project.org/](http://www.r-project.org/)). This study was found exempt by the Boston University Medical Campus Institutional Review Board, Boston, Massachusetts.

RESULTS
=======

Of the 1,401 e-mail recipients, 35 were undeliverable. Of the 1,366 delivered e-mails, 197 responses were obtained, yielding a response rate of 14.4%. [Table 1](#tbl1){ref-type="table"} illustrates the data obtained from questions related to use in clinical settings. Of respondents, 142 (72%) recommend the use of bright light therapy. Among these, all but 1 (99%) recommend the use of bright light therapy for SAD, and 78 (55%) recommend its use for nonseasonal major depression. All but one of those who recommend bright light therapy do so in outpatient settings, and only 11% of those who recommend its use would do so among inpatients.

###### 

Data Obtained From the Survey of Use of Bright Light Therapy in Clinical Settings (N = 197)

  Question                                                                                                         Respondents, n (%)^[a](#tblfn4){ref-type="table-fn"}^   Results^[b](#tblfn5){ref-type="table-fn"}^
  ---------------------------------------------------------------------------------------------------------------- ------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1\. Do you recommend bright light therapy to your patients?                                                      197 (100)                                               Yes: 142 (72)^[c](#tblfn6){ref-type="table-fn"}^
   a. For how long have you been recommending bright light therapy?                                                124 (63)                                                10.8 ± 8.3, 0.2--50, y
   b. Do you recommend the use of bright light therapy to patients with SAD?                                       142 (72)                                                Yes: 141 (99)^[c](#tblfn6){ref-type="table-fn"}^
    To what portion of your patients with SAD do you recommend bright light therapy?                               134 (68)                                                83 ± 29, 5--100, %
    How long does it usually take for clinical response to bright light therapy in SAD?                            91 (46)                                                 2.4 ± 2 wk, 0.5 wk--3 mo
   c. Do you recommend the use of bright light therapy to patients with nonseasonal major depression?              142 (72)                                                Yes: 78 (55)^[c](#tblfn6){ref-type="table-fn"}^
    To what portion of your patients with nonseasonal major depression do you recommend bright light therapy?      86 (44)                                                 24 ± 26, 0--100, %
    How long does it usually take for clinical response to bright light therapy in nonseasonal major depression?   31 (16)                                                 2.9 ± 1.9 wk, 0.5 wk--2 mo
   d. How long do you recommend a patient use bright light therapy in a single treatment period?                   135 (69)                                                ≥ 1 mo: 100 (74)^[c](#tblfn6){ref-type="table-fn"},[d](#tblfn7){ref-type="table-fn"}^
   e. Do you recommend bright light therapy for inpatients, outpatients, or both?                                  142 (72)                                                Outpatients: 141 (99)^[c](#tblfn6){ref-type="table-fn"}^ Inpatients: 16 (11)^[c](#tblfn6){ref-type="table-fn"}^
  2\. What light-delivery device do you recommend (eg, box, lamp, visor, pad)?                                     123 (62)                                                Box or lamp: 101 (71)^[c](#tblfn6){ref-type="table-fn"},[d](#tblfn7){ref-type="table-fn"}^
   a. What light intensity do you recommend?                                                                       118 (60)                                                10,000 lux: 85 (72)^[c](#tblfn6){ref-type="table-fn"}^ 2,500 lux: 12 (10)^[c](#tblfn6){ref-type="table-fn"}^ Other/nonresponse: 21 (18)^[c](#tblfn6){ref-type="table-fn"}^
   b. What session duration do you recommend?                                                                      139 (71)                                                \< 30 min: 13 (9)^[c](#tblfn6){ref-type="table-fn"},[d](#tblfn7){ref-type="table-fn"}^ 30 min: 104 (75)^[c](#tblfn6){ref-type="table-fn"},[d](#tblfn7){ref-type="table-fn"}^ ≥ 1 h: 10 (7)^[c](#tblfn6){ref-type="table-fn"},[d](#tblfn7){ref-type="table-fn"}^ Other: 12 (9)^[c](#tblfn6){ref-type="table-fn"},[d](#tblfn7){ref-type="table-fn"}^

Number who responded to this question (percent of total respondents who responded to this question). If respondents answered yes to the first question, they were shown the remainder of questions found in [Table 1](#tbl1){ref-type="table"}; however, if respondents answered no to that question, they were not shown the remaining questions in [Table 1](#tbl1){ref-type="table"}. All of those who answered yes to the index question (72% of respondents) also responded to questions 1b, 1c, and 1e.

Values presented as n (%) and mean ± SD, range.

Percent yes calculated as (number yes) ÷ (number responses to this question).

Responses to these questions were highly variable, as they were free-text entry. For 1d, common responses were provided in weeks, months, number of seasons, or specific months. Question 2 responses tended to specify type (eg, box, lamp, visor), manufacturer, or model name, although many indicated simply that they deferred to patient preference. Most respondents to 2b selected 1 of the 2 options provided (ie, 30 min or 2 h), whereas others provided specific lengths of time (eg, 1 h) or ranges.

Abbreviation: SAD = seasonal affective disorder.

[Table 2](#tbl2){ref-type="table"} elaborates on various factors that limit the use of bright light therapy. Lack of insurance coverage was the most commonly selected limitation (100 respondents, 55%), followed by limited knowledge (65 respondents, 36%), and patient preference (64 respondents, 35%). [Table 3](#tbl3){ref-type="table"} catalogs provider perception of bright light therapy efficacy for specific disorders and parallels the data presented by Fischer and colleagues.[@bib14] Bright light therapy was consistently thought to be efficacious as an adjunctive treatment more often than as monotherapy. Adjunctive bright light therapy was considered efficacious for SAD by 181 respondents (95% of those who responded to any adjunctive category), for subsyndromal SAD by 175 (92%), and recurrent nonseasonal major depression by 101 (53%), whereas monotherapy bright light therapy was considered efficacious for SAD by 140 (73% who responded to any monotherapy category) and for recurrent nonseasonal major depression by 21 (11%). We report the cumulative demographics of those who completed our survey in [Table 4](#tbl4){ref-type="table"}. Over 90% of respondents answered each of the voluntary demographic questions.

###### 

Limitations to Use of Bright Light Therapy^[a](#tblfn1){ref-type="table-fn"}^

  Limitation                                            Respondents, n (%)^[b](#tblfn2){ref-type="table-fn"}^
  ----------------------------------------------------- -------------------------------------------------------
  Not covered by insurance                              100 (55)
  Limited knowledge of bright light therapy             65 (36)
  Patient preference                                    64 (35)
  Patient compliance concerns                           57 (31)
  Cumbersome to use                                     49 (27)
  Limited efficacy                                      36 (20)
  Not on treatment algorithms                           31 (17)
  Not approved by the US Food and Drug Administration   17 (9)
  Unclear mechanism of action                           17 (9)
  Concerns of cost^[c](#tblfn3){ref-type="table-fn"}^   9 (5)
  Side effects^[c](#tblfn3){ref-type="table-fn"}^       7 (4)

Respondents could select as few or as many of the options above as they wanted. Of the respondents, 181 (92%) selected at least 1 option. The mean number of items selected was 2.4.

Number of respondents who selected this option. Percent of respondents calculated as (number who selected this option) ÷ (number who selected any option = 181).

Cost-related concern was the most common write-in answer, followed by concern of side effects such as risk of manic overshoot, headache, eye strain, or retinal safety.

###### 

Use of Bright Light Therapy in Specific Clinical Conditions (N = 197)^[a](#tblfn8){ref-type="table-fn"}^

  Condition                                                                                                           Monotherapy Yes, n (%)   Adjunct Yes, n (%)
  ------------------------------------------------------------------------------------------------------------------- ------------------------ --------------------
  Nonseasonal major depressive disorder, single episode                                                               22 (11)                  90 (47)
  Nonseasonal major depressive disorder, recurrent                                                                    21 (11)                  101 (53)
  Seasonal affective disorder                                                                                         140 (73)                 181 (95)
  Subsyndromal seasonal affective disorder ("winter blues")                                                           171 (90)                 175 (92)
  Negative symptoms in schizophrenia                                                                                  4 (2)                    22 (12)
  Neurotic, stress-related, and somatoform disorders (including anxiety, posttraumatic, and acute stress disorders)   8 (4)                    28 (15)
  Primary (nonorganic) sleep disorders                                                                                57 (30)                  95 (50)
  Jet lag syndrome                                                                                                    108 (56)                 121 (64)
  Antepartum or postpartum depression^[b](#tblfn9){ref-type="table-fn"}^                                              4 (2)                    3 (2)
  Bipolar depression^[b](#tblfn9){ref-type="table-fn"}^                                                                                        6 (3)

All but 5 respondents provided at least 1 response (yes or no) to the use of bright light therapy as monotherapy; therefore, the percent listed in parentheses under monotherapy equals (number yes) ÷ (192). Similarly, 7 respondents provided no responses related to adjunctive use of bright light therapy; percent under adjunct equals (number yes)/(190).

Use of bright light therapy in antepartum or postpartum depression was the most common write-in for monotherapy bright light therapy, whereas bipolar depression was the most common write-in for adjunctive bright light therapy.

###### 

Demographics of the Respondents to the Survey of Use of Bright Light Therapy (N = 197)

  Question                                                          Respondents, n (%)   Responses[a](#tblfn10){ref-type="table-fn"}
  ----------------------------------------------------------------- -------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------
  Level of training                                                 196 (99)             Postresidency: 159 (81)[b](#tblfn11){ref-type="table-fn"} Resident: 37 (19)[b](#tblfn11){ref-type="table-fn"}
  Percent of practice outpatient                                    188 (95)             80 ± 33, 0--100, %
  Percent of practice inpatient[c](#tblfn12){ref-type="table-fn"}   183 (93)             17 ± 32, 0--100, %
  Practice setting                                                  192 (97)             Urban: 104 (54)[b](#tblfn11){ref-type="table-fn"} Suburban: 80 (42)[b](#tblfn11){ref-type="table-fn"} Rural: 7 (4)[b](#tblfn11){ref-type="table-fn"}
  How long practicing medicine (including residency)                183 (93)             23.3 ± 15.4, 1--57 y
  Gender                                                            194 (98)             Male: 108 (56)[b](#tblfn11){ref-type="table-fn"} Female: 85 (44)[b](#tblfn11){ref-type="table-fn"} Other/deferred: 1 (\< 1)[b](#tblfn11){ref-type="table-fn"}
  Entered contact information to be entered for iPad drawing        166 (84)             NA

Values presented as n (%) and mean ± SD, range.

Percent equals (number with particular response) ÷ (number responding to this question).

Respondents were counted as having responded to inpatient if 100% of their practice was reported to be outpatient, as the response was necessarily 0% inpatient.

Abbreviation: NA = not applicable.

Independent χ^2^ tests were performed to compare responses to the index question (Do you recommend bright light therapy?) and responses to each of the potential limitations. The 4 limitations associated with bright light therapy nonuse that met our a priori level of significance of .05 are shown in [Table 5](#tbl5){ref-type="table"}; limited knowledge of bright light therapy and its absence in treatment algorithms are the 2 limitations most highly associated with nonuse. We performed similar χ^2^ tests related to demographics, and the only demographic feature associated with bright light therapy use with an α \< .05 was level of training (χ^2^~1~ = 30.6, *P* \< 1 × 10^−7^); practicing psychiatrists were more likely to recommend bright light therapy than those respondents in residency (81% versus 35%, respectively).

###### 

χ^2^ Tests Accounting for Bright Light Therapy Nonuse

  Variable                                    χ^2^~1~                   \% of Those Who Recommend Bright Light Therapy Citing This Limitation   \% of Those Who Do Not Recommend Bright Light Therapy Citing This Limitation
  ------------------------------------------- ------------------------- ----------------------------------------------------------------------- ------------------------------------------------------------------------------
  Limited knowledge of bright light therapy   59.6 *P* \< 1 × 10^−13^   17                                                                      75
  Patient preference                          29.0 *P* \< 1 × 10^−7^    44                                                                      4
  Not in treatment algorithms                 13.2 *P* \< .001          10                                                                      31
  Patient compliance concerns                 7.7 *P* \< .01            35                                                                      15

DISCUSSION
==========

It is surprising that 72% of respondents indicated that they recommend the use of bright light therapy, particularly in view of the limited discussion it receives. We suspect that this finding may be a result of our low response rate despite incentivizing survey completion with a drawing for a free iPad. The minimal estimate of those who recommend bright light therapy is 10% (142 affirmative responses divided by 1,366 delivered e-mails). Bright light therapy is used most commonly for SAD and subsyndromal SAD; however, its use for nonseasonal depression is significantly less. Even among this cohort in whom a significant majority considers the use of bright light therapy for seasonal depression, only 10% consider it as monotherapy for nonseasonal depression, with half of respondents considering the adjunctive use of bright light therapy for nonseasonal depression.

The use of bright light therapy tends to be considered much more commonly in outpatient settings than in inpatient settings despite the rapidity of efficacy[@bib9]--[@bib11] and the ability to monitor treatment adherence in a controlled setting. It appears that inpatient use of bright light therapy is largely unexplored in clinical settings. Although this questionnaire did not specify whether "inpatient" referred to medical/surgical or psychiatric hospitals, we suspect that bright light therapy could have applications in both settings.

Insurance coverage and cost stood out as the most salient barriers to clinical use of bright light therapy; however, we understand that many insurance companies will cover the cost of light-delivery devices with a letter from prescribing physicians, particularly for SAD. Beyond this, it may be prudent for psychiatric clinics to provide rental light-delivery devices to patients for a period of time, thus alleviating the upfront cost of the device,[@bib15] and inpatient settings may do well to invest in a small fleet of light-delivery devices given the absence of recurring costs and potential to hasten treatment response and perhaps even shorten length of hospital stay. Were Medicare to approve light-delivery devices as durable medical equipment and the FDA to approve them for the management of depression, insurance companies might be more likely to provide coverage for these devices---particularly given the cost savings in the long run for the insurance company, as they represent a one-time cost rather than recurring monthly or trimonthly costs for medication refills.

Finally, [Table 5](#tbl5){ref-type="table"} illustrates that gaps in knowledge of bright light therapy---in terms of data on efficacy, logistics of use, and potential side effects---is a potentially remediable barrier to broader use of bright light therapy by practicing psychiatrists. Consistent with a recent review of depression clinical practice guidelines that found limited mention of bright light therapy or other chronotherapeutic interventions,[@bib16] our data suggest that its inclusion may contribute to greater prevalent use. Readers are referred to additional online resources from nonprofit organizations regarding bright light therapy and allied chronotherapies such as the Society for Light Treatment and Biological Rhythms (<http://www.slbtr.org/>) and the Center for Environmental Therapeutics (<http://www.cet.org/>).

Responding to Bias
------------------

The largest limitation of this survey centers on the low response rate. We suspect that those with the strongest feelings regarding bright light therapy would be more likely to complete a survey on the treatment. As such, the proportion of respondents who reported using bright light therapy most likely represents an inflated estimate of the true proportion of the population who use the treatment. It was surprising that 72% of respondents reported bright light therapy use, which is actually higher than the number of hospitals using bright light therapy per the European survey to which we anticipated comparing our results (69.8%).

We considered several possible methods to correct for our low response rate. We were unable to obtain cumulative demographic data regarding Massachusetts Psychiatric Society members in order to compare demographics of respondents to assess generalizability. We elected not to follow up on a random sampling of nonrespondents to investigate reasons for nonresponse, as Massachusetts Psychiatric Society members had already received 3 unsolicited e-mails. We further suspected that if the potential for an iPad were insufficient incentive for their response to 3 e-mails, then a fourth would almost certainly yield even less. The first half of respondents was slightly more likely to recommend bright light therapy than the second half of respondents (75% versus 68%, respectively), and, more specifically, the 148 who responded prior to the third e-mail that was entitled "Drawing for free iPad in 4 days" were more likely to indicate bright light therapy use than the 50 survey respondents after this e-mail (74% versus 65%, respectively), suggesting that the potential to win an iPad elicited a cohort of respondents that was slightly less favorably disposed to bright light therapy. Finally, response rates from 2 previous, voluntary surveys disseminated among Massachusetts Psychiatric Society members were 11% and 16%, suggesting that the response rate for our survey was roughly equivalent to those of previous surveys.

Because this survey was Web-based, it is possible that younger e-mail recipients were more likely to respond than those with less technological savvy. Several survey recipients responded to the e-mail saying that the hyperlink was inoperable; however, this appeared to be a function of the safety settings of the recipients' e-mail clients, as the site was accessible when the URL was copied and pasted into the Internet browser. Only 35 of the 1,401 e-mails were undelivered; hence, this was unlikely to have biased responses significantly. Finally, we also considered that our Massachusetts sample of those who not only are practicing in a state with a heavy academic influence (ie, the highest academic medical centers per capita in the United States) but also are affiliated with an active psychiatric society could bias toward those with a greater awareness of recent evidence on the use of bright light therapy.
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